S

Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250

Watchlist Manager
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Watchlist
Price: 104 000 KRW -0.76% Market Closed
Market Cap: 2.4T KRW
Have any thoughts about
Sam Chun Dang Pharm Co Ltd?
Write Note

Net Margin
Sam Chun Dang Pharm Co Ltd

2.5%
Current
-3%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
2.5%
=
Net Income
5.1B
/
Revenue
208.2B

Net Margin Across Competitors

Country KR
Market Cap 2.4T KRW
Net Margin
2%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 744.2B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Net Margin
35%
Country US
Market Cap 373.9B USD
Net Margin
17%
Country US
Market Cap 258.4B USD
Net Margin
19%
Country CH
Market Cap 200.6B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 180.7B CHF
Net Margin
35%
Country US
Market Cap 146.9B USD
Net Margin
7%
No Stocks Found

Sam Chun Dang Pharm Co Ltd
Glance View

Market Cap
2.4T KRW
Industry
Pharmaceuticals

SAM CHUN DANG PHARM Co., Ltd. engages in the manufacture of pharmaceuticals. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2000-10-04. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Company’s products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.

Intrinsic Value
11 241.66 KRW
Overvaluation 89%
Intrinsic Value
Price
S

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
2.5%
=
Net Income
5.1B
/
Revenue
208.2B
What is the Net Margin of Sam Chun Dang Pharm Co Ltd?

Based on Sam Chun Dang Pharm Co Ltd's most recent financial statements, the company has Net Margin of 2.5%.